Biopolym. Cell. 2021; 37(6):428-437.
Structure and Function of Biopolymers
Development of the method of isolation and purification of the recombinant human interleukin-7
1, 2Lutsenko T. M., 1Motronenko V. V.
  1. National Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute"
    37, Peremohy Ave, Kyiv, Ukraine, 03056
    120/4, bld "Zh" Kozatskaya Str, Kyiv, Ukraine, 03022


Aim. To develop a method for isolation and purification of recombinant human interleukin-7 from bacterial inclusion bodies. Methods. Protein synthesis via fermentation, densitometry, refolding method of gel filtration, two-stage chromatographic purification of the protein. Results. The inclusion bodies obtained via fermentation in E.coli cells contained recombinant human interleukin-7, which was solubilized at 22° C for 1 hour in the following buffer solution: 7M of guanidine hydrochloride, 100mM of Tris-HCl, 0.1 % Tween-20 and 50mM of dithiothreitol. Renaturation was conducted by replacing the buffer on column XK26 / 40 (GE Healthcare) with Sephadex G-25 fine equilibrated Clark-Labs solution containing L-arginine hydrochloride and tween-20. Subsequent purification of rIL-7 on the gel filtration column was performed in two stages: at the first stage, purification of rIL-7 was performed on a column packed with 20 ml of Q sepharose, at the second stage, the rIL-7 fraction purified on Q sepharose was purified on SP sepharose. Elution of rIL-7 was performed using double-stage gradient NaCL (0.2 and 0.7M) in a buffer 0.05 M of KH2PO4/NaOH with pH 6.0; 0.1 M of L-arginine; 0.1 % Tween-80. Conclusions. The amount of the target protein after all the proposed stages of purification was 10 % with the purity ratio about 95 %, which is sufficient for further development of the various pharmaceutical forms.
Keywords: interleukin-7, inclusion bodies, refolding, gel filtration, renaturation.


[1] Grigorieva SM, Starosyla DB, Rybalko SL, Motronenko VV, Lutsenko TM, Galkin OYu. Effect of recombinant human interleukin-7 on Pseudo-monas aeruginosa wound infection. Ukr Biochem J. 2019; 91(5): 7-15.
[2] Galkin OY, Lutsenko TM, Gorshunov YV, Motronenko VV. Development of the method for microbiological purity testing of recombinant human interleukin-7-based product. Ukr Biochem J. 2017; 89(3): 52-9.
[3] Slyvka AV, Okunev OV. Molecular mechanisms of versatile biological activity of interleukin-7. Biopolym Cell. 2014; 30(5): 349-57.
[4] Lutsenko TN, Kovalenko MV, Galkin OY. Validation of biological activity testing procedure of recombinant human interleukin-7. Ukr Biochem J. 2017; 89(1): 82-9.
[5] Lutsenko TM, Galkin OYu. Substantiation of biotechnological approaches of producing interleukin-7 recombinant human. Proceedings of the Belarusian State Technological University. Series "Chemistry, technology of organic substances and biotechnology". 2015; 4(177): 188-97.
[6] McElroy CA, Dohm JA, Walsh STR. Structural and biophysical studies of the human IL-7/IL-7Ra complex. Structure. 2009; 17(1): 54-65.
[7] Galkin OY. Comparative characteristic of the methods of protein antigens epitope mapping. Ukr Biochem J. 2014; 86(4): 164-77.
[8] Natochii T, Motronenko V. Comparative characteristics of biotechnological approaches to obtaining recombinant human cytokines in bacterial expressing systems. Innov Biosyst Bioeng. 2019; 3(3): 128-45.
[9] Ouellette T, Destrau S, Ouellette T, Zhu J, Roach JM, Coffman JD, Hecht T, Lynch JE, Giardina SL. Production and purification of refolded recombinant human IL-7 from inclusion bodies. Protein Expr Purif. 2003;30(2):156-66
[10] Luo Y, Kong X, Xu A, Jin S, Wu D. Expression, purification, and functional characterization of recombinant human interleukin-7. Protein Expr Purif. 2009;63(1):1-4.
[11] Mirzaei M, Jardin B, Elias CB, Prakash S. Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). Appl Biochem Biotechnol. 2008;151(1):93-103.
[12] Toghraie FS, Sharifzadeh SM, Ramezani A, Mahmoudi Maymand E, Yazdanpanah-Samani M, Ghaderi A. Cloning and Expression of Recombinant Human Interleukin-7 in Chinese Hamster Ovary (CHO) Cells. Rep Biochem Mol Biol. 2017;6(1):66-73.
[13] Motronenko V, Lutsenko T, Galkin A, Gorshunov Y, Solovjova V. Optimization of the culture medium composition to increase the biosynthesis of recombinant human interleukin-7 in Escherichia coli. J Microbiol Biotechnol Food Sci. 2020; 9(4): 761-8.
[14] Galkin OY, Besarab OB, Gorshunov YV, Ivanova OM. New monoclonal antibodies to the Chlamydia trachomatis main outer membrane protein and their immunobiological properties. Ukr Biochem J. 2019; 91(3): 90-8.
[15] Sokol AA, Grekov DA, Yemets GI, Galkin AYu, Shchotkina NV, Dovghaliuk AA, Telehuzova OV, Rudenko NM, Romaniuk OM, Yemets I M. Comparison of bovine pericardium decellularization protocols for production of biomaterial for cardiac surgery. Biopolym Cell. 2020; 36(5): 392-403.
[16] Patent of Ukraine No.112442 "Method of obtaining of recombinant human IL-7 via recombinant molecule, containing cDNA copy of a structural part of spliced cDNA of human IL-7 gene and expression DNA vector"
[17] Thapa A, Shahnawaz M, Karki P, Raj Dahal G, Sharoar MG, Yub Shin S, Sup Lee J, Cho B, Park IS. Purification of inclusion body-forming peptides and proteins in soluble form by fusion to Escherichia coli thermostable proteins. Biotechniques. 2008;44(6):787-96.
[18] Nikolaenko IV, Goncharenko VS, Shimko NN, Galkin AIu. [Isolation of surface antigen of hepatites B virus]. Ukr Biokhim Zh (1999). 2007;79(2):114-22.
[19] Gilchuk PV. Evaluation of renaturation methods for industrial obtaining of recombinant proteins from Escherichia coli inclusion bodies in biologically active form. Biopolym Cell. 2004; 20(3): 182-91.
[20] Sokol AA, Grekov DA, Yemets I, Galkin O, Shchotkina N, Rudenko N, Yemets I. Biocompatiblibility analysis of the decellularized bovine pericardium. Cell Organ Transplantol. 2020; 8(2): 193-7.
[21] Galkin A, Komar A, Gorshunov Y, Besarab A, Soloviova V. New monoclonal antibodies to the prostate-specific antigen: obtaining and studying biological properties. J Microbiol Biotechnol Food Sci. 2019; 9(3); 573-7.
[22] Golembiovska OI, Galkin AYu, Besarab AB. Development and validation of a dissolution test for ursodeoxycholic acid and taurine from combined formulation. Scientific Study & Research - Chemistry & Chemical Engineering, Biotechnology, Food Industry. 2019; 20(3); 377-94.
[23] van de Loosdrecht AA, Beelen RHJ, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MMAC. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Meth. 1994; 174(31): 311-20.